NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
News|Articles|August 1, 2008
August 2008 Oncology News International
Advertisement
Cover Story
- High cost of biologics takes a toll on hem/onc practices
- FDA cracks down on counterfeit cancer cure products
DEPARTMENTS
Focus on Breast Cancer
- Mastectomy rates for early breast cancer are on the upswing at one Mayo Clinic
- Is breast MRI primed for widespread use as a high-risk screening tool?
- Vantage Point: Risk factors will guide the imaging paradigm
Focus on Lung Cancer
- Anti-IGF-1R antibody plus chemo active in advanced non-small-cell lung cancer
News & Analysis
- Oncologic drug safety: Separating fact from fiction
Focus on Prostate Cancer
- Dual antiangiogenic therapy plus chemo is active in advanced prostate cancer
Advertisement
Related to this article
In 60 patients undergoing gastrectomy, pre-consultation video aids shortened in-person consent visits and no patient had high decisional conflict.
The robotic endoscopy system obtained detrusor muscle in 94% of resected bladder lesions among the first 20 patients treated in the VIABLE study.
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
Phase 1a data in 16 patients with recurrent glioblastoma established a recommended dose for expansion of LP-184 for a planned phase 1b/2a combination trial.
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
The FDA approved pimicotinib for TGCT based on phase 3 MANEUVER data showing durable responses and improved pain, stiffness, and function.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
European Commission Expands Melflufen Label to Third-Line Multiple Myeloma
5